Patents by Inventor Ursula Bodendorf

Ursula Bodendorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST
    Publication number: 20230323419
    Abstract: The present application pertains inter alia to an isolated vertebrate cell suitable for recombinant expression of a polypeptide of interest, wherein the vertebrate cell is altered to impair the function of the endogenous protease matriptase and wherein said cell comprises at least one heterologous polynucleotide encoding a polypeptide of interest and wherein the polypeptide of interest is secreted by the cell. It was found that using respective vertebrate cells for producing a recombinant polypeptide of interest significantly reduces clipping of the polypeptide of interest that is secreted into the cell culture medium. Also provided are improved production and screening methods.
    Type: Application
    Filed: October 26, 2022
    Publication date: October 12, 2023
    Inventors: Holger Laux, Sandrine Romand, Ursula Bodendorf
  • Vertebrate cells and methods for recombinantly expressing a polypeptide of interest
    Patent number: 11512335
    Abstract: The present application pertains inter alia to an isolated vertebrate cell suitable for recombinant expression of a polypeptide of interest, wherein the vertebrate cell is altered to impair the function of the endogenous protease matriptase and wherein the cell comprises at least one heterologous polynucleotide encoding a polypeptide of interest and wherein the polypeptide of interest is secreted by the cell. It was found that using respective vertebrate cells for producing a recombinant polypeptide of interest significantly reduces clipping of the polypeptide of interest that is secreted into the cell culture medium. Also provided are improved production and screening methods.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 29, 2022
    Assignee: Novartis AG
    Inventors: Holger Laux, Sandrine Romand, Ursula Bodendorf
  • Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
    Publication number: 20170044587
    Abstract: The present application pertains inter alia to an isolated vertebrate cell suitable for recombinant expression of a polypeptide of interest, wherein the vertebrate cell is altered to impair the function of the endogenous protease matriptase and wherein said cell comprises at least one heterologous polynucleotide encoding a polypeptide of interest and wherein the polypeptide of interest is secreted by the cell. It was found that using respective vertebrate cells for producing a recombinant polypeptide of interest significantly reduces clipping of the polypeptide of interest that is secreted into the cell culture medium. Also provided are improved production and screening methods.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 16, 2017
    Applicant: Novartis AG
    Inventors: Holger Laux, Sandrine Romand, Ursula Bodendorf
  • Kallikrein 7 modulators
    Patent number: 8309596
    Abstract: The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: November 13, 2012
    Assignee: Novartis AG
    Inventors: Stefanie Flohr, Stefan Andreas Randl, Nils Ostermann, Ulrich Hassiepen, Frederic Berst, Ursula Bodendorf, Bernd Gerhartz, Andreas Marzinzik, Claus Ehrhardt, Josef Gottfried Meingassner
  • Kallikrein 7 modulators
    Publication number: 20100256144
    Abstract: The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.
    Type: Application
    Filed: June 26, 2008
    Publication date: October 7, 2010
    Inventors: Stefanie Flohr, Stefan Andreas Randl, Nils Ostermann, Ulrich Hassiepen, Frederic Berst, Ursula Bodendorf, Bernd Gerhartz, Adreas Marzinzik, Claus Ehrhardt, Josef Gottfried Meingassner